A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc.

As her memory faded from Alzheimer’s disease in her late 50s, Tammy Maida began to lose track of her life. Car keys, ...

In the early stages of Alzheimer’s disease, people may have trouble following conversations, repeat themselves, or struggle ...

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus on existing disease areas.

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

By 2050, over 1.7 million Canadians are projected to be living with dementia. This represents an increase of 187 per cent ...

WORTHINGTON — Though the group is no stranger to performing on stage, JD Productions will take its first bows at ...

TORONTO -- Biomarkers pointing to increased risk for Alzheimer's disease were markedly reduced with the investigational cholesteryl ester transfer protein (CETP) inhibitor obicetrapib relative to ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...